Equities

Basilea Pharmaceutica AG Allschwil

Basilea Pharmaceutica AG Allschwil

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)41.30
  • Today's Change0.75 / 1.85%
  • Shares traded34.24k
  • 1 Year change+15.52%
  • Beta1.0767
Data delayed at least 15 minutes, as of Nov 22 2024 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in CHF

The 6 analysts offering 12 month price targets for Basilea Pharmaceutica AG Allschwil have a median target of 76.85, with a high estimate of 120.00 and a low estimate of 52.00. The median estimate represents a 86.08% increase from the last price of 41.30.
High190.6%120.00
Med86.1%76.85
Low25.9%52.00

Earnings history & estimates in CHF

Basilea Pharmaceutica AG Allschwil reported annual 2023 earnings of 0.86 per share on Feb 13, 2024.
Average growth rate+25.00%
More ▼

Revenue history & estimates in CHF

Basilea Pharmaceutica AG had revenues for the full year 2023 of 157.63m. This was 6.68% above the prior year's results.
Average growth rate+4.37%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.